BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page1of15
Research
RESEARCH
Clinical and cost effectiveness of mobile phone
supported self monitoring of asthma: multicentre
randomised controlled trial
OPENACCESS
DermotRyanclinicalresearchfellow1 ,DavidPriceprofessorofprimarycarerespiratorymedicine1
,
StanDMusgraveresearchfellow1 ,ShwetaMalhotraresearchassistant1 ,AmandaJLeeprofessor
of medical statistics2 , Dolapo Ayansina research fellow2 , Aziz Sheikh director of research3 , Lionel
Tarassenko professor of electrical engineering, director4 , Claudia Pagliari senior lecturer5 , Hilary
Pinnock senior clinical research fellow3
1AcademicCentreofPrimaryCare,DivisionofAppliedHealthSciences,UniversityofAberdeen,AberdeenAB252ZD,UK;2MedicalStatistics
Team,DivisionofAppliedHealthSciences,UniversityofAberdeen,Aberdeen;3AllergyandRespiratoryResearchGroup,CentreforPopulation
HealthSciences,UniversityofEdinburgh,EdinburghEH89DX;4InstituteofBiomedicalEngineering,UniversityofOxford,OxfordOX37DQ;5eHealth
ResearchGroup,CentreforPopulationHealthSciences,UniversityofEdinburgh,Edinburgh
Abstract consultationsweresimilarinbothgroups,withsimilarhealthcarecosts.
ObjectiveTodeterminewhethermobilephonebasedmonitoring Overall,themobilephoneservicewasmoreexpensivebecauseofthe
improvesasthmacontrolcomparedwithstandardpaperbasedmonitoring expensesoftelemonitoring.
strategies. ConclusionsMobiletechnologydoesnotimproveasthmacontrolor
DesignMulticentrerandomisedcontrolledtrialwithcosteffectiveness increaseselfefficacycomparedwithpaperbasedmonitoringwhenboth
analysis. groupsreceivedclinicalcaretoguidelinesstandards.Themobile
technologywasnotcosteffective. SettingUKprimarycare.
TrialregistrationClinicalTrialsNCT00512837. Participants288adolescentsandadultswithpoorlycontrolledasthma
(asthmacontrolquestionnaire(ACQ)score≥1.5)from32practices. Introduction
InterventionParticipantswerecentrallyrandomisedtotwicedaily
Globally,anestimated300millionpeoplehaveasthma,
recordingandmobilephonebasedtransmissionofsymptoms,druguse,
presentingaconsiderableandincreasingburdenofdiseaseto
andpeakflowwithimmediatefeedbackpromptingactionaccordingto healthcaresystems,families,andpatients.1Despitetwodecades
anagreedplanorpaperbasedmonitoring.
ofasthmaguidelines,2asthmaremainspoorlycontrolledina
MainoutcomemeasuresChangesinscoresonasthmacontrol substantialproportionofpeople.3Structuredasthma
questionnaireandselfefficacy(knowledge,attitude,andselfefficacy management—whichintheUnitedKingdomispredominantly
asthmaquestionnaire(KASE-AQ))atsixmonthsafterrandomisation. deliveredinprimarycare4—canimproveoutcomesintermsof
Assessmentofoutcomeswasblinded.Analysiswasonanintentionto exacerbations,admissionstohospital,anddayslostfromschool
treatbasis. andwork.5Theconceptofsupportedselfmanagement,engaging
ResultsTherewasnosignificantdifferenceinthechangeinasthma bothcliniciansandpatientsindeliveringandimplementing
controlorselfefficacybetweenthetwogroups(ACQ:meanchange regularmonitoringofcontrolandadjustmentoftreatment,isa
0.75inmobilegroupv0.73inpapergroup,meandifferenceinchange keyrecommendationofnationalandinternationalguidelines.67
−0.02(95%confidenceinterval−0.23to0.19);KASE-AQscore:mean ThetheoreticalmodeldevelopedbyGlasziouandcolleagues,
change−4.4v−2.4,meandifference2.0(−0.3to4.2)).Thenumbersof usingasthmaasanexemplar,describesthecomplementaryand
patientswhohadacuteexacerbations,steroidcourses,andunscheduled evolvingrolesofperiodicsupportfromprofessionalsand
Correspondence to: D Ryan, Woodbrook Medical Centre, 28 Bridge St, Loughborough LE11 1NH dermotryan@doctors.org.uk
Extra material supplied by the author (see http://www.bmj.com/content/344/bmj.e1756?tab=related#webextra)
Appendix 1: Protocol for escalation and intervention by nurse
Appendix 2: Additional tables (unit sources and costs; per protocol analysis; intention to treat analysis)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page2of15
RESEARCH
ongoingselfmonitoringbypatients.8Ourrecentqualitative Patientswithanincompatiblehandsetbutwhosubscribedtoa
studysuggeststhatpeoplewithasthmaperceivearoleformobile compatiblenetworkwereofferedtheopportunityofborrowing
technologyinaidingtransitionfromcliniciansupportedphases ahandsetforthedurationofthetrial.
whilecontrolisgainedtoeffectiveselfmanagementduring Potentialparticipantsattendedabaselineassessmentvisitin
maintenancephases.9
theirgeneralpracticeatwhichtheywereprovidedwithfurther
Pooradherencetomonitoringanddrugsisapotentially informationaboutthetrial,eligibilitywasconfirmedwiththe
modifiablefactorassociatedwithpoorcontrol.10Incontrastwith sevenquestionversionoftheACQ(whichincludesFEV (forced
1
paperdiarymonitoring,inwhichasfewas6%ofreadingsmight expiratoryvolumeinonesecond)inadditiontothesixquestions
berecorded,11trialswithelectronicrecordingdeviceshave describedbelowasaprimaryoutcomemeasure),andwritten
shownratesofcomplianceofover60%,12especiallyifthe consentwasobtained.Allconsentingpatientswhometthe
patientisawarethattheirhealthbehaviourisbeingobserved.13 eligibilitycriteriawereenrolledintothetrial.
Timelyfeedbackofresultstothepatientcanobjectivelyshow
severityofsymptomsandtheimpactofcompliancewithdrug Primary outcome measures
treatment.Mobilephones,themostpervasiveandaccessible
Asthmacontrolquestionnaire(ACQ)—Theprimaryoutcome
formoftechnologyglobally,14offerahighlyconvenientsystem
measurewasthechangeinasthmacontrolbetweenbaseline
forselfmonitoringcoupledwithinstantaneousfeedback,
andsixmonthsasmeasuredbyACQ(sixquestionversion).2021
potentiallyengagingthepatientinthemonitoringand
TheACQmeasuresclinicalgoalsofasthmamanagementona
managementoftheirasthma.
scaleof0(goodcontrol)to6(poorcontrol),isresponsiveto
SetwithintheMedicalResearchCouncil’sframeworkforthe change,20andhasaminimumimportantdifferencewithin
designandevaluationofcomplexinterventions,1516ourphase individualsof0.5.22Postaladministrationgivescomparable
IIItrialwasunderpinnedbypreliminaryworkthatsuggested resultswithsupervisedcompletion.23
thatmobilephonebasedselfmonitoringofasthmacarewas
Knowledge,attitude,andselfefficacyasthmaquestionnaire
feasibletodeliverandacceptabletobothpatientsand
(KASE-AQ)—Selfefficacywasmeasuredasthechangein
clinicians.91217Wehypothesisedthat,inadolescentsandadults
KASE-AQbetweentheinterventionandcontrolgroupsatsix
withpoorlycontrolledasthmaofferedtreatmentaccordingto
months.TheKASE-AQhasthreeindependentlyscored
theBritishThoracicSociety/ScottishIntercollegiateGuideline
subscalesof20itemsofwhichweusedtwo:“selfefficacy,”
Network(BTS-SIGN)asthmaguideline,6theuseofmobile
whichmeasuresperceivedabilitytocontrolasthma,and
phonebasedmonitoringoflungfunctionandsymptomswith
“attitudetoasthma.”24Scoresrangefrom20(minimumscore)
feedbacktopatientswouldimprovebothcontrolofasthmaand
to100andareresponsivetochange.25Weomittedtheoutdated
patientselfefficacyatsixmonthscomparedwithpaperbased knowledgesubscale.
monitoringstrategies.
Secondary outcome measures
Methods
Fulldetailsofthesecondaryoutcomemeasuresofinterestare
Ourmulticentre,investigatorblindedrandomisedcontrolled inthepublishedprotocol.15Briefly,weincluded:
trialwasconductedinUKprimarycarein2008-9.Adetailed •Mini-asthmaqualityoflifequestionnaire(mini-AQLQ):
protocolhasbeenpublishedelsewhere18;wemadenoimportant
scorefrom1(greatestimpairment)to7,withaminimum
changestoourmethodsduringthetrial. importantdifferenceof0.526
•Adverseoccurrencesobtainedfromthepracticerecords,
Practice recruitment
includingadmissionsforexacerbationsofasthma(defined
TheprimarycareresearchnetworksinNorfolkandYarmouth, asacutedeteriorationsofasthmaforwhichthepatient
EastKent,NorthofEngland,andEssexandHertfordshire soughtmedicaladvice),prescribedcoursesoforalsteroids,
identifiedandrecruitedpractices. andunscheduledconsultations
•Prescriptionsofasthmadrugsrecordedinthepatients’
Participants
healthcarerecord
Werecruitedpatientsaged12andoverwhowereregistered
•Modifiedpatientenablementinstrument(mPEI):scaleof
withparticipatingpractices,hadpoorlycontrolledasthma 0to12(mostenabled)27
(definedasscore≥1.5onasthmacontrolquestionnaire(ACQ)19),
andhad,orwerewillingtoborrow,acompatiblemobilephone •Engagementwithprocess(proportionofpatientsdefaulting
handsetandacontractwithacompatiblenetwork.Weexcluded fromclinicalfollow-up).
peoplewhohadotherlungdisease,wereunabletocommunicate
inEnglish,orwerereceivingspecialistcareforsevere/difficult Baseline assessment
asthma,andthosewhosegeneralpractitioneradvisedagainst
Weundertookabaselineassessmentcomprisinghistoryof
inclusionformajorsocial/clinicalproblems.
asthma,currentsmokingstatus,presenceofcomorbidity,and
FEV withaPikometer(nSpireHealth,Enfield,UK).Theuse
Recruitment of patients 1
ofthePikometertorecordpeakflowswasdemonstratedand
Wesearchedpracticecomputerdatabasestoidentifypotentially ametergiventothepatientforusethroughoutthetrial.The
eligiblepatients.AftertheGPhadscreenedthecomputerlists, ACQ,KASE-AQ,mini-AQLQ,andmPEIquestionnaireswere
wesentpostalinvitationstoalleligiblepatients,withuptoone selfcompletedundersupervision.
writtenreminder.
Randomisation and protection against bias
Oneresearcher(SDMorSM)prescreenedrespondentsby
telephonetodeterminewhethertheyfulfilledthecriterionof Allconsentingparticipantswerestratifiedbypracticeand
poorlycontrolledasthmaandwhethertheyhadacontractwith centrallyrandomised(HealthServicesResearchUnit,University
acompatiblemobilephonenetworkandacompatiblehandset. ofAberdeen)tomobilephoneorpaperbasedmonitoringwith
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page3of15
RESEARCH
a1:1allocationwithrandomblocksizesoftwoorfour; Data collection
telephonerandomisationensuredconcealmentuntilthetreatment
Aresearcherblindedtoallocationcollectedprimaryoutcome
wasassigned.Thepracticenurseinformedthepatientof dataatthefinaltrialvisit;non-attendeesweresentthe
allocationtoensuretheresearcherswereblindedtoallocation
questionnairesbypost.Interimdatawerecollectedbypostal
throughoutdatacollectionandanalysis.
questionnairesatthreemonths.Thepracticeasthmanurses
recordedthedurationofeachreviewattheendofthe
Mobile phone monitoring
consultationandnotedwhetherthepatient’sasthmawasnow
Thepracticenurseforwardedcontactdetailsofpatientsallocated controlledandwhetherafurtherappointmentwasneeded.The
totheintervention(mobile)grouptoOBSMedical(Abingdon, researcherextracteddataonadverseevents(including
UK),whocontactedthepatientatatimeconvenienttothem admissions,unscheduledasthmaconsultations),asthma
(normallywithinaweek),downloadedthet+Asthmaapplication treatmentcategorisedbyBTS-SIGNguidelinestep,6anduseof
(fig1⇓)ontotheir(oraloaned)phone,testeditsfunctionality, healthcareresourcesoverthesixmonthtrialperiodfromthe
trainedthepatientinitsuse,provideddetailsofwebaccess, primarycarerecordsatbaselineandattheendofthetrial.
andfollowedupwithatechnicalsupportcallafteroneweekof Questionnairedatawerescannedonthetrialdatabase.Data
use. fromrecordsandothertrialdatawereenteredmanually.
Thet+Asthmaapplicationenabledtwicedailyrecordingand
Sample size calculations
transmissionofsymptoms,druguse,andpeakflow.Themean
ofthefivebestpeakflowvaluesinthefirst50readings(after UsinganestimatedstandarddeviationofchangeinACQscore
discardingthelowestfiveandhighestfivereadings,which of0.25,19weestimatedthatasamplesizeof125perarmwould
preliminaryworksuggestedwereoftenoutliers28)wastakento have90%powerwithatwosided5%significanceleveltodetect
bethetargetpeakflowvalue(100%)andusedtodefinethe adifferenceinmeanchangeinACQscoreof0.1ormore
80%and60%thresholdsforatrafficlightdisplay.Asnewdata betweengroups.Withastandarddeviationof13.3,25asample
weregenerated,thetargetpeakflowvaluewasadjustedtothe sizeof39ineacharmwouldhave90%powerwithatwosided
meanofthefivebestpeakflowvalues(afterdiscardingoutliers) 5%significanceleveltodetectameandifferenceinmean
inthemostrecent50readings.Therecordedpeakflowwas KASE-AQ(selfefficacyscale)scoreof10ormorebetween
displayedwithinthetrafficlightzonesandthepatientwas groups.
promptedtofollowtheiragreedactionplan(fig1⇓).Incursion
intotheredoramberzonestriggeredcontactbyanasthmanurse Data analysis
fromOBSMedicalonthenextworkingday.Appendix1on
Ourmainanalysiswasonanintentiontotreat(ITT)basis.We
bmj.comgivestheprotocolforthesesupportcalls.Boththe
assumedthatparticipantswhodidnotattendthethreeorsix
patientandtheirclinicianwereabletoaccessthepatientdata
monthassessmenthadnotimprovedtheircontrolandtheir
recordviaapasswordprotectedwebsite.
previousresultswerethereforecarriedforward.30Aperprotocol
analysiswasundertakenasasensitivityanalysis.
Paper based monitoring
Atbaselinewedescribedgroupsintermsofsociodemographic
Patientsinthecontrol(paper)groupwereaskedtokeepapaper
factors,historyofasthma,ACQ,mini-AQLQ,KASE-AQ,and
diary,recordingthesamedataastheinterventiongroup
mPEIscores.Wecomparedprespecifiedchangesbetween
(symptoms,druguse,andpeakflowreadings)twicedaily.
groupsfrombaselineinoutcomemeasuresusingappropriate
univariatetechniques(ttest,Mann-Whitneytest).Weused
Clinical care in both groups
repeatedmeasuresanalysisofvariance,adjustedforageand
Toensurethatourtrialspecificallytestedtheimpactofthe sex,toexaminetrendsovertimeinACQ,mini-AQLQ,
technology,weoptedtoprovidethepapergroupwiththesame KASE-AQ,andmPEIscoresbothbetweenandwithingroups.
clinicalcareastheinterventiongroup,ratherthanusing Alltwowayinteractionsbetweenoutcomeandageandsex
(probablylessintensive)usualcareasacomparator.Before wereexamined.
randomisation,thepracticeasthmanursedelivereda30minute WecomparedtheproportionofparticipantswhoseACQand
standardisededucationsessionencompassinginformationon mini-AQLQscorehadimprovedbymorethan0.5(theminimum
asthma,asthmatreatment,inhalertechnique,monitoring,and importantdifference),31theproportioninwhomasthmaremained
apersonalisedasthmaactionplanbasedonbothsymptomsand poorlycontrolled(ACQ>1.519),andtheproportionwhose
peakflowscompletedinaccordancewiththeadviceofthe asthmawas“wellcontrolled”(ACQ<0.7519)atsixmonths.
BTS-SIGNasthmaguideline.Instructiononmobileorpaper WeassessedcostsfromtheperspectiveoftheNHS.Thetotal
monitoringwasprovidedafterrandomisationaccordingto
costofthemonitoringserviceforaprojectedmaximumof156
allocation.
participantswasallocatedtoeachparticipantwiththeestimated
Throughoutthetrialthepractices’asthmanurseprovidedclinical reimbursedtransmissioncosts.Costswereestimatedbyusing
careinaccordancewiththestepwiseapproachadvocatedby unitcostsobtainedfromstandardsources32-34(seetableAin
theBTS-SIGNasthmaguideline.6Patientswerereviewed
appendix2onbmj.comfordetails).Weusedtteststocompare
monthly(includingtheoptionoftelephonereviewsaccording costsbetweengroups.
topreferenceandclinicalcondition)untilthenursejudgedthat
Allanalyseswereagreedapriori.Wedidnotplan,orundertake,
controlwasachievedonthebasisofclinicalmonitoring.
anyinterimanalysis.
Recognitionofcontrolinthecontextofaclinicalreviewwas
discussedduringthetraining.29Whencontrolwasattained,the
Results
patientwasdischargedfrommonthlyfollow-upbutwas
encouragedtocontinuemonitoringonamaintenancebasis, Recruitment
seekingprofessionaladviceifneeded.
Figure2showstheflowofpatientsthroughthetrial⇓.From32
practices(totallistsize311926)computersearchesidentified
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page4of15
RESEARCH
apotentiallyeligiblepopulationof13101(mean(SD)age48.2 mobilegroupand74(55%)inthepapergroup),andthenine
(17.9):63%female),ofwhom1020wereexcludedbytheir patientsnottreatedaccordingtoBTS-SIGNstepsatbaseline
practice.Atotalof12081postalinvitationswereissued:1016 werereceivingarecommendedtreatmentschedulebytheend
people(8.4%)expressedaninterestinparticipatingandwere ofthetrial(fig4⇓).Therewasnosignificantdifferencebetween
prescreenedforeligibility(poorcontrolandcompatiblemobile thegroupsinthenumberofacuteattacks,steroidcourses
phoneandnetwork).The393potentiallyeligiblepatientswere prescribed,unscheduledGPornurseconsultations,outofhours
invitedtoattendthebaselineassessmentand288gaveinformed visits,attendancesatemergencydepartment,oradmissions
consentandwererandomised:145tothemobilegroupand143 (table5⇓).
tothepapergroup.TenpeoplehadmissingorincompleteACQ
scoresatbaselineandwereexcludedafterrandomisation, Trends over time
leaving139patientsineachgroupfortheintentiontotreat
Analysisoftherepeatvaluesoverthethreetimepointsofthe
analysis.
trialisshownintableCinappendix2onbmj.com.Therewas
nosignificantdifferenceintheimprovementovertimeinany
Baseline characteristics
oftheoutcomemeasures.
Demographiccharacteristicsofparticipants,FEV,smoking
1
status,currentasthmatreatment,andbaselinequestionnaire Cost of the monitoring services
scoresweresimilarinbothgroups(table1⇓).Patientswhodid
Table6givesdetailsofthecosttothehealthserviceofproviding
notcompletethefinalquestionnaireswereolder(51.7(SD17.7)
thetwomonitoringservices⇓.Theonlysignificantcost
v40.7(SD17.3);P<0.001)thanpatientswhocontributedtothe
differencebetweenthetwogroupswasinrelationtothe
finaldatacollection,withnosexdifference.
telemonitoringservice(about£69(€83,$108)perpatient).The
meancostofprovidingrespiratorycare(includingthenurse
Primary outcomes
monitoringreviews)was£246(SD£226)inthemobilegroup
Asthmacontrol—Therewasnosignificantdifferenceinthe comparedwith£245(SD£201)inthepapergroup(mean
changeinasthmacontrolinthetwogroups(ACQ:meanchange difference−£1.26(−£51.47to£48.95).
0.75inmobilegroupv0.73inpapergroup,meandifferencein
change−0.02(95%confidenceinterval−0.23to0.19)(table Discussion
2⇓).Figure3showschangesovertime⇓.Overhalfthepatients
Summary of main findings
inbothgroupsimprovedbymorethantheminimumimportant
difference(table3⇓).Atsixmonths,29/139(21%)of Theuseofmobilephonetechnologydidnotsignificantly
participantsinthemobilegroupand31/139(22%)ofthepaper improveclinicaloutcomes,orincreaseselfefficacy,compared
grouphadachievedthe“wellcontrolled”thresholdofACQ withpaperbasedmonitoringwhendeliveredinthecontextof
≤0.75.19Similarly,69/139(50%)ofparticipantsinthemobile
guidelinestandardclinicalcareforthemanagementofasthma.
groupand67/139(48%)ofthepapergroupstillscoredabove Healthcarecostsweresimilarinbothgroups,withthe
the“poorlycontrolled”thresholdofACQ≥1.50.19
telemonitoringexpensesbeinganadditionalcostinthemobile
Selfefficacy—Theintentiontotreatanalysisfoundnosignificant group.
differencebetweenthegroupsinchangeintheselfefficacyand
attitudescalesoftheKASE-AQ(table2⇓). Strengths and limitations
Weexceededourestimatedsamplesizefortheintentiontotreat
Secondary outcomes
analysis,thoughnotfortheperprotocolsensitivityanalysis.
Asthmarelatedqualityoflife—Similarly,theintentiontotreat Theresults,however,areconsistent,anditisunlikelythata
analysisshowednosignificantdifferencebetweenthegroups smallerattritionratewouldalterourconclusions.Ourapriori
inchangeinmini-AQLQscore(table2⇓),thoughmorepatients basisofcarryingthepreviousresultforward18assumesthat
inthemobilegroupimprovedtheirqualityoflifebymorethan non-respondersdidnotimprovetheircontrol,whichprobably
theminimumimportantdifferencethaninthepapergroup(table underestimatesthedegreeofchangeinbothgroups.
3⇓). Thelowrecruitmentrate(2.4%ofthoseinvited)reflectsboth
Enablement—Theintentiontotreatanalysisfoundnosignificant thelowresponserate(8.4%ofthoseinvited)andour
differencebetweenthegroupsinchangeinthemPEIscores requirementthatparticipantsshouldhavepoorlycontrolled
(table2⇓). asthmaandacompatiblemobilephonesystem.Aslightlyhigher
proportionoftheparticipantswasfemale,comparedwiththe
Per protocol sensitivity analysis potentiallyeligiblepopulation.The10patientsexcludedafter
randomisationbecauseofmissingbaselineACQscoreswere
Theperprotocolanalysisincludedonlydatafromparticipants
distributedbetweenthetwoarms(fourinthemobilegroup,six
whohadcompleteinformationforeachrespectivequestionnaire inthepapergroup),andwererecruitedfromeightdifferent
atalltimepoints.Theresultsofthissensitivityanalysis
practices,reducingtheriskthatthisintroducedimportantbias.
confirmedthefindingsoftheintentiontotreatanalysis(see
tableBinappendix2onbmj.com). Ourmulticentretrialwasconductedinprimarycare,thesetting
formostasthmacareintheUK,andincludedbothanintention
Attendanceforreviews,changeintreatment, totreatanalysisandaperprotocolsensitivityanalysis.Webuilt
and unscheduled healthcare onextensiveformativework,whichunderpinnedthehypothesis
andinformedthepracticaldesignoftheinterventionandthe
Inbothgroupsthemediannumberofasthmaconsultationswas outcomesmeasured.9121723Althoughthepatientsandnurses
two,with37%ofthepatientsinbothgroupsattendingonlythe
wereclearlyawareofthemodeofmonitoringthattheywere
baselineandonefollow-upappointment(table4⇓).Mostpatients
using,ourtrialproceduresensuredthattheresearcherswho
inbothgroupshadincreasedtreatmentwithasthmadrugs
undertookdatacollectionandthetrialstatisticianswereblinded
accordingtotheBTS-SIGNtreatmentsteps(82(59%)inthe
toallocation(forexample,randomisationwasundertakenby
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page5of15
RESEARCH
thepracticenurses,technicalissuesweredealtwithbyOBS regulardrugtreatment45thanthosewithalreadywellcontrolled
Medical,patientswereinstructednottorevealallocation,inthe asthma.Ourtrial,whichrecruitedpeoplewithpoorercontrol
eventofaninadvertentbreachasecondresearcherattendedthe andlowerbaselinespirometryresultsthanothertrials,3839did
practiceforsubsequentdatacollection). notfindabeneficialeffectinthisgroup.
Interpretationwithreferencetootherresearch Conclusions and implications
Ourfindingsexemplifythechallengesofevaluatingcomplex Inpeoplewithpoorlycontrolledasthma,themobilephonebased
eHealthinterventions35andtheconcernthatpotentialbenefits modelofmonitoringdidnotofferanyadvantagesoverand
havethusfartendednottobesubstantiatedbysubsequent abovepaperbasedcarewhenguidelinestandardclinicalsupport
empiricalevidence.36Somestudiesusingmobilephones37and serviceswereprovidedtobothgroups.Whilemobilephone
internetbasedmonitoringhaveshownbenefitinadults3839and technologywillappealtosomepeople,1718itisnotthecrucial
children40whencomparedwith“usualcare.”Usualcare, ingredientandcarriescostimplications.Itsplaceinclinicalcare
however,islikelytobeconsiderablylessintensivethanthat mightdependonwhetheritisacosteffectiveoptionfor
experiencedbyinterventiongroups,sothatitisoftenimpossible enhancing“usualcare”tothestandardsrecommendedby
todeterminewhethertheobservedbenefitsinthesetrialswere guidelines.46Policymakersinternationallyshouldconsiderthe
becauseoftheenhancedclinicalcareorthetechnological findingsfromthismulticentretrialwhenconsideringthemerits
intervention.Toovercomethis,weprovidedthesamestructured ofinvestmentinmodelsofasthmacarebasedontelehealthcare.
clinicalandeducationalinterventioninbothgroupsandshowed
thatwhentheonlydifferenceisthemodeofmonitoringand Wethanktheofficersoftheprimarycareresearchnetworksfor
associatedfeedback,thelinkwithmobilephonetechnologyhad supportingpracticerecruitment,thepractices,practicenurses,and
nosignificanteffect. administrativestafffortheiractiveparticipation,andthepatientswho
Ourhypothesis,buildingonformativework,9121317was gavetheirtimetoparticipateinthetrial.WethankAndrewWilsonand
predicatedonthetheorythatusingamobilephonetomonitor NeilKendleforservingontheITSCandBrianMcKinstryandChris
andreceiveinstantaneousfeedbackontheirasthmacontrol Burtonwhoofferedadviceascollaborators.
wouldhelppatientstointegratemanagementintoeverydaylife, Contributors:DRinitiatedtheideaforthestudyandwithHPledthe
engagethemmorefullyintheircare,andthuspotentially developmentoftheprotocol,securingoffunding,studyadministration,
improveasthmacontrol.Patientsinbothgroups,however, dataanalysis,interpretationofresults,andwritingofthepaper.DP,AS,
attendedasimilarnumberofmonthlyclinicalreviews, CP,andLTweregrantholderswhocontributedtodevelopmentofthe
suggestingthatthemobilephonemonitoringdidnotimprove protocolandsecuringoffunding.DP,AS,andCPalsocontributedto
compliancewithcare.Similarly,mostpatientsinbothgroups studyadministration,dataanalysis,interpretationofresults,andwriting
steppeduptheirtreatmentduringthecourseofthetrial. ofthepaper.LTcontributedtointerpretationofresultsandwritingof
Participationinthetrialprobablyresultedingreaterengagement thepaper.SDMandSMundertookthedatacollection.AJLandDA
ofpatientsandasthmanursesinbothgroupswith“guideline werethetrialstatisticians.Allauthorshadfullaccesstoallthedataand
standardcare”(asopposedto“usualcare”),potentially wereinvolvedininterpretationofthedata.DRandHPwrotetheinitial
contributingtotheimprovementweobservedinbothgroups. draftofthepaper,towhichalltheauthorscontributed.DRandHPare
Spontaneousimprovementoverthetimescaleofthetrialis studyguarantors.
anotherplausibleexplanation. Funding:ThisstudywasfundedbyAsthmaUK(projectID07/047).Piko
DespitethesignificantimprovementsinACQscoreinboth peakflowmetersweredonatedbynSpireHealth.HPissupportedby
groups,onlyaboutafifthachievedthewellcontrolledthreshold aprimarycareresearchcareerawardfromthechiefscientist’soffice
ofACQ=0.75.Whileithasbeenshownthatevenbettercontrol oftheScottishGovernment.
canbeachievedintrialswithmaximaldosesofdrugsinselected Competinginterests:AllauthorshavecompletedtheICMJEuniform
patientswithasthma,41thedegreeofimprovementweobserved disclosureformatwww.icmje.org/coi_disclosure.pdf(availableon
isofthesameorderasthatshownin“reallife”trials,42inwhich requestfromthecorrespondingauthor)anddeclare:DRhasspoken
adherenceisvariableandcomorbidityiscommon.Toincrease onbehalfofAstraZeneca,Nycomed,MSD,AlkAbello,Chiesi,Novartis,
generalisability,wedidnotexcludesmokerssosomeoverlap PfizerandBoehringerIingelheim.Hehasundertakenadvisoryworkfor
withchronicobstructivepulmonarydiseaseispossible. AstraZeneca,MSD,Novartis,Uriach,Mundipharma,Orion,andNapp.
Thecostofthet+asthmaservicewasadditionaltothehealth DPhasconsultantarrangementswithBoehringerIngelheim,
servicecosts,whichwereotherwisesimilarinbothgroups, GlaxoSmithKline,Merck,Mundipharma,Novartis,andTeva.Inthepast
makingitthemoreexpensiveoption.Thismightnotextrapolate fiveyears,heorhisresearchteamhavereceivedgrantsandsupport
directlytonormalclinicalpracticewhere,forexample, forresearchinrespiratorydiseasefromUKNationalHealthService,
economiesofscaleinaregionalservicecouldreducethecost Aerocrine,AstraZeneca,BoehringerIngelheim,GlaxoSmithKline,Merck,
perpatient.Inaddition,manyotherfactorswillaffectbothcosts Mundipharma,Novartis,Nycomed,Pfizer,andTeva.Hehasspoken
andbenefits.Technologicaladvances,suchassmartphone forAstraZeneca,BoehringerIngelheim,Chiesi,GlaxoSmithKline,Merck,
applications,willincreasefunctionalityandwidespreadadoption Mundipharma,Pfizer,andTeva.HehassharesinAKL,whichproduces
mightdrivedowncosts.Aspartofthecommercialarrangement phytopharmaceuticals.HeisthesoleownerofResearchinRealLife.
withOBSMedicaladditionalclinicalsupportwasavailableto SDMhasreceivedinstitutionalgrantsupportfromMerckandCo,AKL
themobilegroupfromthet+asthmanurse,thoughits Technologies,Chiesi,andMundipharmaASservesonWHO’smHealth
contributionisunclearasitwasnotacloselymonitored andInformationTechnologyforPatientSafetyExpertWorkingGroups
componentofthetrial. andisanadvisertoNHSConnectingforHealth’sEvaluationProgramme.
HeisaconsultanttoALKandPhadiaandhasreceivedsupportfrom
Arecentsystematicreviewconcludedthattelehealthcarein
Napp,Pfizer,andChiesiforresearchadvice.LTisacofounderof,
asthmacouldhavearoleinreducinghospitaladmissionsin
advisorto,andholdssharesinOBSMedical.Hecontributedtothe
highriskpatientsandinthosewithseveredisease,43andsome
designoft+asthmaandofthetrial,buthadnoroleintheday-to-day
studieshavesuggestedthatthosewithpoorlycontrolledasthma
conductofthestudyorstatisticalanalysis.Hisworkontelehealthcare
mightbemorereadytocomplywithnovelmonitoring44ortake
isfundedbytheNIHRBiomedicalResearchCentreProgramme.HP
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page6of15
RESEARCH
Whatisalreadyknownonthistopic
Mobilephonesofferahighlyconvenientsystemforselfmonitoringcoupledwithinstantaneousfeedback,potentiallyengagingpatients
inthemonitoringandselfmanagementoftheirasthma
Someinterventionsusingmobilephonesinasthmacarehaveshownbenefitcomparedwith“usualcare,”butitisoftenimpossibleto
determinewhethertheobservedbenefitswerebecauseofthemobilephoneinterventionortheassociatedenhancedclinicalcare
Whatthisstudyadds
Themobilephonebasedmodelofmonitoringdidnotofferanyclinicaladvantagesoverandabovepaperbasedcarewhenguideline
standardclinicalsupportserviceswereprovidedtobothgroups
Clinicallyrelevantimprovementswereseeninbothgroups,suggestingthatthetelemonitoringwasnotthecrucialingredientinimproving
outcomes
Themobilephonebasedmodelofasthmacarewasmoreexpensivethanpaperbasedmodel
hasspokenforAstraZeneca,BoehringerIngelheim,Chiesi, 24 WigalJK,StoutC,BrandonM,WinderJA,McConnaughyK,CréerTL,etal.The
knowledge,attitude,andself-efficacyasthmaquestionnaire.Chest1993;104:1144-8.
GlaxoSmithKline,Pfizer,andTevaandundertakenadvisorygroupwork 25 LemaigreV,VandenBerghO,VanHasseltK,DePeuterS,VictoirA,VerledenG.
forChiesi. Understandingparticipationinanasthmaself-managementprogram.Chest
2005;128:3133-9.
Ethicalapproval:ThisstudywasapprovedbyHertfordshireresearch 26 JuniperEF,GuyattGH,CoxFM,FerriePJ,KingDR.Developmentandvalidationofthe
ethicscommittee(07/H0311/126),andgovernanceapprovalwas MiniAsthmaQualityofLifeQuestionnaire.EurRespirJ1999;14:32-8.
27 HowieJGR,HeaneyDJ,MaxwellM,WalkerJJ.Acomparisonofpatientenablement
providedbytheparticipatingNHStrusts. instrumentagainsttwoestablishedsatisfactionscalesasanoutcomemeasureofprimary
Datasharing:Noadditionaldataavailable. careconsultations.FamPract1998;15:165-71.
28 CobernW.Asthmaself-managementusingmobiletelephonetechnology.www.ibme.ox.
ac.uk/bsp/publications/pdf-files/Will%20Cobern%202007%20DPhil%20thesis.pdf.
1 MasoliM,FabianD,HoltS,BeasleyR.Theglobalburdenofasthma.GlobalInitiativefor 29 PinnockH,FletcherM,HolmesS,KeeleyD,LeyshonJ,PriceD,etal.Settingthestandard
Asthma,2003.www.ginasthma.com. forroutineasthmaconsultations:adiscussionoftheaims,processandoutcomesof
2 McIvorRA,ChapmanKR.Thecomingofageofasthmaguidelines.Lancet reviewingpeoplewithasthmainprimarycare.PrimCareRespirJ2010;19:75-83.
2008;372:1021-2. 30 WhiteIR,HortonNJ,CarpenterJ,PocockSJ.Strategyforintentiontotreatanalysisin
3 RabeKF,AdachiM,LaiCK,SorianoJB,VermeirePA,WeissKB,etal.Worldwideseverity randomisedtrialswithmissingoutcomedata.BMJ2011;342:d40.
andcontrolofasthmainchildrenandadults:theglobalasthmainsightsandrealitysurveys. 31 GuyattGH,JuniperEF,WalterSD,GriffithLE,GoldsteinRS.Interpretingtreatmenteffects
JAllergyClinImmunol2004;114:40-7. inrandomisedtrials.BMJ1998;316:690-3.
4 CampbellS,ReevesD,KontopantelisE,MiddletonE,SibbaldB,RolandM.Qualityof 32 CurtisL.Unitcostsofhealthandsocialcare2008.PersonalSocialServicesResearch
primarycareinEnglandwiththeintroductionofpayforperformance.NEnglJMed Unit,UniversityofKent.www.pssru.ac.uk.
2007;357:181-90. 33 DepartmentofHealth.Nationalscheduleofreferencecosts2007-08forNHSTrustsand
5 GibsonPG,PowellH,WilsonA,AbramsonMJ,HaywoodP,BaumanA,etal. PCTs.www.dh.gov.uk/en/Publicationsandstatistics/Publications/
Self-managementeducationandregularpractitionerreviewforadultswithasthma. PublicationsPolicyAndGuidance/DH_098945.
CochraneDatabaseSystRev2002;3:CD001117. 34 BritishMedicalAssociationandRoyalPharmaceuticalSociety.BritishNationalFormulary
6 BritishThoracicSociety/ScottishIntercollegiateGuidelineNetwork.BritishGuidelineon September2008.BMJGroupandPharmaceuticalPress,2008.
theManagementofAsthma.Thorax2008;63(suppl4):1-121. 35 CatwellL,SheikhA.EvaluatingeHealthinterventions:theneedforcontinuoussystemic
7 GlobalInitiativeforAsthma(GINA).Globalstrategyforasthmamanagementand evaluation.PLoSMed 2009;6(8):e1000126.
prevention.2010.www.ginasthma.org. 36 BlackAD,CarJ,PagliariC,AnandanC,CresswellK,BokunT,etal.TheimpactofeHealth
8 GlasziouP,IrwigL,MantD.Monitoringinchronicdisease:arationalapproach.BMJ onthequalityandsafetyofhealthcare:asystematicoverview.PLoSMed
2005;330:644-8. 2011;8(1):e1000387.
9 PinnockH,SlackR,PagliariC,PriceD,SheikhA.Understandingthepotentialroleof 37 OstojicV,CvoriscecB,OstojicSB,ReznikoffD,Stipic-MarkovicA,TudjmanZ.Improving
mobilephone-basedmonitoringonasthmaself-management:qualitativestudy.ClinExp asthmacontrolthroughtelemedicine:astudyofshort-messageservice.TelemedJE
Allergy2007;37:794-802. Health2005;11:28-35.
10 ClatworthyJ,PriceD,RyanD,HaughneyJ,HorneR.Thevalueofself-reportassessment 38 RasmussenLM,PhanarethK,NolteH,BackerV.Internet-basedmonitoringofasthma:
ofadherence,rhinitisandsmokinginrelationtoasthmacontrol.PrimCareRespirJ along-term,randomizedclinicalstudyof300asthmaticsubjects.JAllergyClinImmunol
2009;18:300-5. 2005;115:1137-42.
11 YoosHL,KitznianH,MeMullenA,HendersonC,SidoraK.Symptommonitoringin 39 VanderMeerV,BakkerM,vandenHoutWB,RabeK,SterkPJ,KievitJ,etal.
childhoodasthma:arandomizedclinicaltrialcomparingpeakexpiratoryflowratewith Internet-basedself-managementpluseducationcomparedwithusualcareinasthmaa
symptommonitoring.AnnAllergyAsthmaImmunol 2002;88:283-91 randomizedtrial.AnnInternMed2009;151:110-20.
12 RyanD,CobernW,WheelerJ,PriceD,Tarassenko.Mobilephonetechnologyinthe 40 JanR-L,WangJ-Y,HuangM-C,TsengS-M,SuH-J,LiuL-F.Aninternet-basedinteractive
managementofasthma.JTelemedTelecare.2005;11(suppl1):43-6. telemonitoringsystemforimprovingchildhoodasthmaoutcomesinTaiwan.TelemedJ
13 ReddelHK,ToelleBG,MarksGB,WareSI,JenkinsCR,WoolcockAJ.Analysisof EHealth2007;13:257-68.
adherencetopeakflowmonitoringwhenrecordingofdataiselectronic.BMJ 41 BatemanED,BousheyHA,BousquetJ,BusseWW,ClarkTJH,PauwelsRA,etal.Can
2002;324:146-7. guideline-definedasthmacontrolbeachieved?AmJRespirCritCareMed
14 InternationalTelecommunicationUnion.Keyglobaltelecomindicatorsfortheworld 2002;170:836-44.
telecommunicationservicesector.ITU,October2010.www.itu.int. 42 PriceDB,MusgraveSD,ShepstoneL,HillyerEV,SimsEJ,GilbertRFT,etal.Leukotriene
15 CampbellNC,MurrayE,DarbyshireJ,EmeryJ,FarmerA,GriffithsF,etal.Designing antagonistsasfirst-lineoradd-onasthma-controllertherapy.NEngJMed
andevaluatingcomplexinterventionstoimprovehealthcare.BMJ2007;334;455-9. 2011;364:1695-707.
16 CraigP,DieppeP,MacIntyreS,MitchieS,NazarethI,PetticrewM.Developingand 43 McLeanS,ChandlerD,NurmatovU,LiuJ,PagliariC,CarJ,etal.Telehealthcarefor
evaluatingcomplexinterventions:newguidance.MedicalResearchCouncil,2008. asthma.CochraneDatabaseSystRev2010;10:CD007717.
17 ClelandJ,CaldowJ,RyanD.Attitudesofpatientsandstafftousingmobilephone 44 VanderMeerV,vanStelHF,DetmarSB,OttenW,SterkPJ,SontJK.Internet-based
technologytorecordandgatherasthmadata:aqualitativestudy.JTelemedTelecare self-managementoffersanopportunitytoachievebetterasthmacontrolinadolescents.
2007;13:85-9. Chest 2007;132;112-9.
18 RyanD,PinnockH,LeeAJ,TarrasenkoL,PagliariC,SheikhA,etal.TheCYMPLAtrial. 45 LiuWT,HuangCD,WangCH,LeeKY,LinSM,KuoHP.Amobile-telephonebased
Mobilephone-basedstructuredinterventiontoachieveasthmacontrolinpatientswith interactiveselfcaresystemimprovesasthmacontrol.EurRespJ2011;37:310-7.
uncontrolledpersistentasthma:apragmaticrandomisedcontrolledtrial.PrimCareRespir 46 McLeanS,ProttiD,SheikhA.Telehealthcareforlongtermconditions.BMJ2011;342:d120.
J2009;18:343-5. Accepted:13January2012
19 JuniperE,BousquetJ,AbetzL,BatemanE.Identifying‘well-controlled’andnotwell
controlledasthmausingtheAsthmaControlQuestionnaire.RespirMed2006;100:616-21.
20 JuniperEF,O’ByrnePM,GuyattGH,FerriePJ,KingDR.Developmentandvalidationof Citethisas:BMJ2012;344:e1756
aquestionnairetomeasureasthmacontrol.EurRespJ1999;14:902-7.
21 JuniperEF,SvenssonK,MorkAnn-Christin,StahlE.Measurementpropertiesand Thisisanopen-accessarticledistributedunderthetermsoftheCreativeCommons
interpretationofthreeshortenedversionsoftheasthmacontrolquestionnaire.Respir AttributionNon-commercialLicense,whichpermitsuse,distribution,andreproductionin
Med2005;99:553-8.
anymedium,providedtheoriginalworkisproperlycited,theuseisnoncommercialand
22 JuniperEF,StåhlE,O’ByrnePM.Minimalimportantdifferencefortheasthmacontrol
questionnaire.AmJRespirCritCareMed2001;163:642. isotherwiseincompliancewiththelicense.See:http://creativecommons.org/licenses/by-
23 PinnockH,SheikhA,JuniperE.Concordancebetweensupervisedandpostal nc/2.0/andhttp://creativecommons.org/licenses/by-nc/2.0/legalcode.
administrationoftheMiniAQLQandACQisveryhigh.JClinEpidemiol2005;58:809-14
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page7of15
RESEARCH
Tables
Table1|Baselinecharacteristicsofpeoplewithasthmaallocatedtomobilephoneorpaperbasedmonitoring.Figuresarenumbers
(percentages)unlessstatedotherwise
Mobile(n=145) Paper(n=143)
Mean(SD)age(years) 46.6(18.0) 51.5(17.7)
Female 96(66) 84(59)
Whiteethnicity 141(97) 142(99)
Median(IQR)FEV percentagepredicted* 83.1(71.0-96.6) 80.8(65.3-94.9)
1
Smokingstatus†
Neversmoked 70(49) 72(50)
Ex-smoker 55(38) 54(38)
Currentsmoker 19(13) 16(11)
Treatmentstep:
Step0:nocurrentdrugs 8(6) 7(5)
Step1:shortactingβ agonist 41(29) 33(24)
2
Step2:inhaledsteroid 47(33) 41(30)
Step3:longactingβ agonistorleukotrienereceptorantagonist 42(30) 53(39)
2
Step4:highdosesteroidsoradditionaltreatment 4(3) 3(2)
Treatmentnotinlinewithguidelinetreatmentsteps 3(2) 6(4)
Mean(SD)scoreonquestionnaires:
ACQ 2.32(0.73) 2.29(0.77)
KASE-AQ(selfefficacydomain) 77.4(9.5) 78.0(10.5)
KASE-AQ(attitudedomain) 80.0(7.4) 79.4(7.2)
mini-AQLQ 4.25(0.91) 4.34(1.08)
mPEI 5.83(3.67) 6.93(3.78)
IQR=interquartilerange;ACQ=asthmacontrolquestionnaire;KASE-AQ=knowledge,attitude,andselfefficacyasthmaquestionnaire;AQLQ=asthmaqualityoflife
questionnaire;mPEI=modifiedpatientenablementinstrument.
*Availablefor142inmobilegroupand140inpapergroup.
†Availablefor144inmobilegroupand142inpapergroup.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page8of15
RESEARCH
Table2|Intentiontotreatanalysisofasthmacontrolandselfefficacyinpeoplewithasthmarandomisedtomobilephoneorpaperbased
monitoring
Mean(SD) Meandifferenceof
meanchange(95%
Noingroup Baseline 6months Meanchange(95%CI) CI)
Primaryoutcomes
ACQ:
Mobile 139 2.32(0.73) 1.57(0.99) 0.75(0.61to0.89) −0.02(−0.23to0.19)
Paper 139 2.29(0.77) 1.56(1.09) 0.73(0.57to0.89)
KASE-AQ(selfefficacyscale):
Mobile 110 77.4(9.5) 81.8(11.1) −4.4(−6.1to−2.7) 2.0(−0.3to4.2)
Paper 121 78.0(10.5) 80.4(11.5) −2.4(−3.9to−0.9)
KASE-AQ(attitudescale):
Mobile 118 80.0(7.4) 81.8(9.5) −1.7(−2.9to−0.6) −0.2(−1.6to1.6)
Paper 122 79.4(7.2) 81.2(8.6) −1.8(−2.9to−0.6)
Questionnairebasedsecondaryoutcomes
mini-AQLQ:
Mobile 97 4.25(0.91) 5.0(1.32) −0.75(−0.94to−0.57) 0.10(−0.16to0.34)
Paper 104 4.34(1.08) 4.99(1.34) −0.65(−0.84to−0.46)
mPEI:
Mobile 136 5.83(3.67) 6.79(4.0) −0.96(−1.62to−0.31) 1.19(0.26to2.11)
Paper 35 6.93(3.78) 6.71(3.92) 0.22(−0.44to0.88)
ACQ=asthmacontrolquestionnaire;KASE-AQ=knowledge,attitude,andselfefficacyasthmaquestionnaire;AQLQ=asthmaqualityoflifequestionnaire;mPEI=modified
patientenablementinstrument.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page9of15
RESEARCH
Table3|ProportionofpeoplewithasthmawhoseACQandmini-AQLQscoreimprovedbymorethanminimumimportantdifference(MID)
atsixmonthsaccordingtorandomisationtomobilephoneorpaperbasedmonitoring
Improvement Deterioration
Noingroup ≥MID <MID <MID ≥MID BetweengroupPvalue
ACQ
Mobile 139 83(60) 44(32) 6(4) 6(4) 0.78
Paper 139 79(57) 44(32) 6(4) 10(7)
mini-AQLQ
Mobile 97 43(80) 3(6) 4(7) 4(7) 0.03
Paper 104 39(58) 16(24) 5(8) 7(10)
ACQ=asthmacontrolquestionnaire;AQLQ=asthmaqualityoflifequestionnaire.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page10of15
RESEARCH
Table4|Useofhealthcareresourcesduringfollow-upinpeoplewithasthmaallocatedtomobilephoneorpaperbasedmonitoring
Mobile(n=140) Paper(n=141)
Mean(SD)asthmaconsultationsduringtrial* 2.4(1.2) 2.7(1.3)
Noattendingfollow-upconsultations:
Baselineclinicalconsultationonly 37(26%) 27(19%)
Baseline+1followup 52 51
Baseline+2follow-ups 28 28
Baseline+3follow-ups 13 16
Baseline+4follow-ups 3 9
Baseline+5follow-ups 5 10
Baseline+6follow-ups 0 0
TotalNooffollow-upconsultations 184 241
Modeofconsultation:
Facetoface 173 231
Telephone 11 10
NowhochangedBTS-SIGNtreatmentstep:
Steppedup 82(59%) 74(55%)
Stepunchanged 50(36%) 50(35%)
Steppeddown 11(8%) 13(9%)
Broughtintolinewithguidelinetreatmentsteps† 3(2%) 6(4%)
*Meandifference0.3(95%confidenceinterval−0.03to0.6),P=0.07.
†P=0.46.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page11of15
RESEARCH
Table5|Detailsofunscheduledcareandacuteexacerbationsduringfollow-upinpeoplewithasthmaallocatedtomobilephoneorpaper
basedmonitoring
Mobilen=140 Papern=141 Pvalue
ConsultationswithGPforasthma:
TotalNoofconsultations 108 85 —
No(%)withatleastone 51(36) 41(29) —
Median(IQR) 0(0-1) 0(0-1) 0.19
Unscheduledgeneralpracticenurseconsultations:
TotalNoofconsultations 86 109 —
No(%)withatleastone 45(32) 62(44) —
Median(IQR) 0(0-1) 0(0-1) 0.07
Outofhoursattendances:
TotalNoofattendances 3 5 —
No(%)withatleastone 3(2) 5(4) —
Median(IQR) 0(0-0) 0(0-0) 0.70
Emergencydepartmentattendances:
TotalNoofattendances 3 0 —
No(%)withatleastone 3(2) 0 —
Median(IQR) 0(0-0) 0(0-0) 0.08
Admissionsforasthma:
TotalNoofadmissions 3 1 —
No(%)withatleastone 3(2) 1(1) —
Median(IQR) 0(0-0) 0(0-0) 0.32
Acuteexacerbations:
TotalNoofexacerbations 74 70 —
No(%)withatleastone 43(31) 45(32) —
Median(IQR) 0(0-1) 0(0-1) 0.84
Steroidcourses:
TotalNoofsteroidcourses 39 43 —
No(%)withatleastone 28(20) 30(21) —
Median(IQR) 0(0-0) 0(0-0) 0.79
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page12of15
RESEARCH
Table6|Mean(SD)costsofserviceprovision(roundedtonearest£)formobilephone(telemonitoring)orpaperbasedmonitoring(control)
Telemonitoring(n=140) Control(n=141) Meandifference(95%CI) Pvalue
Totalhealthcarecosts 315(226) 245(201) −70(−121to−20) 0.006
Totalcostofdeliveringtrialinterventionsaccordingtoallocation 94(12) 28(12) −66(−69to−64) <0.001
Trialnursingcosts 25(12) 28(12) 3(0to6) 0.07
Telemonitoringservicecosts 69 0 — —
Totalcostofhealthcareprovision(excludingtrialinterventions) 53(143) 41(87) −12(−40to16) 0.39
GPrespiratoryconsultations 26(47) 21(42) −6(−16to5) 0.30
Practicenurserespiratoryconsultations 6(12) 8(12) 2(−1to4) 0.26
Secondarycarecosts(outpatientandadmissions) 18(116) 11(56) −7(−29to14) 0.51
Emergencyservices(includingemergencydepartment,outofhours) 3(17) 2(13) −1(−4to3) 0.61
Totalcostofprescriptionsforrespiratorydrugs 167(136) 178(152) 11(−23to45) 0.53
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page13of15
RESEARCH
Figures
Fig1Mobilephonemonitoringsystem.t+Asthmaapplication,runningonwebenabledhandset,allowedpatienttorecord
symptoms,druguse,andpeakflowfromPikometer.Automateddisplayplottedpeakflowasnormal(≥80%greenzone),
inneedofattention(60-79%amberzone),orinneedofurgentaction(<60%redzone)andpromptedpatientstofollow
theiragreedactionplan.Incursionintoredoramberzonesalsotriggeredcontactbyt+AsthmanursefromOBSMedical
onnextworkingdaytoascertainwhathadhappenedandwhatlearningpointshadarisen.Datawereautomaticallytransmitted
tosecurewebsiteonremoteserverhostedbyOBSMedical,everytimeapplicationwasusedbypatient.Patientandclinician
wereabletoaccesspatientdatarecordviapasswordprotectedwebsite,whichalsoprovidedgeneralinformationabout
asthma
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page14of15
RESEARCH
Fig2Flowofpatientsthroughtrialofmobilephoneandpaperbasedmonitoringofasthmacontrol(ACQ=asthmacontrol
questionnaire;KASE-AQ=knowledge,attitude,andselfefficacyasthmaquestionnaire;COPD=chronicobstructivepulmonary
disease;ITT=intentiontotreat)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
BMJ2012;344:e1756doi:10.1136/bmj.e1756(Published23March2012) Page15of15
RESEARCH
Fig3MeanACQscoresadjustedforageandsexatdifferenttimepointsinpeoplewithasthmaaccordingtoallocated
methodofmonitoring
Fig4ChangeinBTS-SIGNstepfrombaselinetosixmonthsinpeoplewithasthmaaccordingtoallocatedmethodof
monitoring
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe:http://www.bmj.com/subscribe
BMJ:
first
published
as
10.1136/bmj.e1756
on
23
March
2012.
Downloaded
from
http://www.bmj.com/
on
24
August
2024
by
guest.
Protected
by
copyright.
